Armor Investment Advisors LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,359 shares of the company’s stock after selling 1,068 shares during the period. Johnson & Johnson makes up about 1.3% of Armor Investment Advisors LLC’s portfolio, making the stock its 26th largest position. Armor Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,290,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in JNJ. Schnieders Capital Management LLC raised its stake in Johnson & Johnson by 0.3% in the first quarter. Schnieders Capital Management LLC now owns 56,499 shares of the company’s stock valued at $7,037,000 after buying an additional 185 shares during the last quarter. Diversified Portfolios Inc. raised its stake in Johnson & Johnson by 69.1% in the first quarter. Diversified Portfolios Inc. now owns 2,373 shares of the company’s stock valued at $296,000 after buying an additional 970 shares during the last quarter. WESPAC Advisors LLC raised its stake in Johnson & Johnson by 93.3% in the first quarter. WESPAC Advisors LLC now owns 4,752 shares of the company’s stock valued at $592,000 after buying an additional 2,294 shares during the last quarter. Advantage Investment Management LLC raised its stake in Johnson & Johnson by 3.7% in the first quarter. Advantage Investment Management LLC now owns 12,579 shares of the company’s stock valued at $1,567,000 after buying an additional 443 shares during the last quarter. Finally, Sigma Investment Counselors Inc. raised its stake in Johnson & Johnson by 88.8% in the first quarter. Sigma Investment Counselors Inc. now owns 15,072 shares of the company’s stock valued at $1,877,000 after buying an additional 7,091 shares during the last quarter. 65.98% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson (NYSE JNJ) traded down 1.01% on Friday, reaching $131.03. The company’s stock had a trading volume of 3,820,814 shares. The firm has a 50-day moving average of $132.89 and a 200 day moving average of $128.36. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The company has a market capitalization of $351.68 billion, a price-to-earnings ratio of 22.17 and a beta of 0.79.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. Johnson & Johnson’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the business earned $1.74 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.56%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

ILLEGAL ACTIVITY WARNING: “Armor Investment Advisors LLC Lowers Position in Johnson & Johnson (JNJ)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/02/armor-investment-advisors-llc-lowers-position-in-johnson-johnson-jnj.html.

Several equities research analysts have recently commented on the stock. BMO Capital Markets reaffirmed a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Friday. UBS AG reaffirmed a “buy” rating and set a $148.00 price target on shares of Johnson & Johnson in a research report on Thursday. Cowen and Company set a $147.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Thursday, August 24th. Jefferies Group LLC set a $145.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Tuesday, August 15th. Finally, J P Morgan Chase & Co upped their price target on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research report on Wednesday, August 16th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $134.60.

In other news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.